Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, gastro-intestinal, pain/analgesic, anti-diabetic, neuro/central nervous system, gynecology, respiratory, dermatology, and cardiac diseases. It also provides vitamins, minerals, and nutrients, as well as mouth wash, shampoos, pregnancy detection kits, and condoms. The company was incorporated in 1973 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for ALKEM
Revenue projections for ALKEM

ALKEM is projected to experience a revenue decline compared to last year, a development that often leads to investor caution. The drop could negatively impact the company's bottom line, as lower revenues typically signal reduced profitability, prompting more conservative investment strategies.

Financial Ratios:

currentRatio 2.761000
forwardPE 24.971203
debtToEquity 11.106000
earningsGrowth 0.042000
revenueGrowth 0.071000
grossMargins 0.632520
operatingMargins 0.088680
trailingEps 180.990000
forwardEps 213.950000

ALKEM's current ratio of 2.761 highlights the company's solid liquidity, indicating that it can easily service its short-term debt. ALKEM's ample cash reserves and current assets ensure that the company is well-positioned to meet its immediate financial liabilities.
ALKEM's Forward PE is in a strong range, indicating that its stock price compares well with its earnings. The stock is not considered overpriced, leaving ample room for growth and making it a promising option for investors looking for value and future returns.
Alkem Laboratories Limited's low Debt-to-Equity ratio means it is not excessively leveraged, implying a reduced financial risk profile. This suggests Alkem Laboratories Limited maintains a well-balanced financial structure, with more emphasis on equity than debt, ensuring greater flexibility and long-term stability.
With a forward EPS greater than its trailing EPS, Alkem Laboratories Limited is expected to see higher profitability this year. The forecasted increase in earnings reflects optimism about the company's financial growth and potential for improved performance over the prior year.

Price projections:

Price projections for ALKEM
Price projections for ALKEM

The price of ALKEM has consistently remained close to the lower end of price projections. This trend may reflect uncertainty in the market regarding the company's ability to deliver on growth expectations.

Recommendation changes over time:

Recommendations trend for ALKEM
Recommendations trend for ALKEM


Recent analysis shows a strong buy bias for ALKEM, encouraging investors to view it as a solid investment option. The positive sentiment surrounding ALKEM suggests it could be an attractive place to allocate funds, motivating potential investors to consider the stock as a valuable part of their portfolio.